This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

WEB REGISTRATION CLOSES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Stephen Spagnol, PhD
Director, Enabling Technologies at Merck
Speaker

Profile

Stephen Spagnol is a Director of Business Development & Licensing, Enabling Technologies at Merck. He leads Search & Evaluation efforts related to Drug Delivery & Formulation, Vaccines & Biologics Bioprocess as well as Genetic Medicines spanning Cell & Gene Therapy, mRNA/RNA Therapeutics and Gene Editing. Prior to Business Development & Licensing, Stephen led Research & Development efforts spanning novel and new modality therapeutics including mRNA Vaccines, RNA Therapeutics and Viral Vector Platforms for Cell & Gene Therapy. He has led development of novel platforms for mRNA/RNA drug delivery technologies and viral vector platforms. He has also led formulation and process development including for late stage/Phase 3 clinical programs. Stephen received a Ph.D. in Chemical Engineering from Carnegie Mellon University and a B.S. in Chemical Engineering from the Pennsylvania State University.

Agenda Sessions

  • Chairman’s Remarks: Next-Generation Delivery Platforms

    1:55pm